Summary

This article presents the final results from the Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice trial [OPTIMIZE; Feres F et al. JAMA 2013], demonstrating that in patients with coronary heart disease who received a drug-eluting stent (DES), cessation of dual antiplatelet therapy 3 or 12 months after implantation did not increase their risk of the composite endpoint of death, myocardial infarction, stroke or major bleeding, or stent thrombosis at 1-year follow-up.